The pharmaceutical sector is witnessing unprecedented investor interest with Amanta Healthcare’s IPO becoming one of the most talked-about public offerings of 2025. The issue was oversubscribed by an impressive 82 times, reflecting massive investor confidence in this Gujarat-based pharmaceutical manufacturer that’s making waves in both domestic and international markets.
Table of Contents
Amanta Healthcare IPO Performance Snapshot
The retail-driven subscription frenzy saw non-institutional investors subscribing at 36.41x and retail investors at 23.35x, demonstrating strong grassroots confidence in the company’s growth prospects. This overwhelming response positions Amanta Healthcare among the year’s most successful IPO launches.
| Amanta Healthcare IPO Details | Information |
|---|---|
| Issue Size | ₹126 Crore |
| Price Band | ₹114 – ₹126 per share |
| Allotment Date | September 4, 2025 |
| Listing Date | September 9, 2025 |
| Current GMP | ₹8.50 (6.75% premium) |
| Expected Listing Price | ₹134.50 |
| Exchanges | BSE & NSE |
Grey Market Premium Analysis
According to latest reports, the Grey Market Premium (GMP) stands at ₹8.50, indicating an estimated listing price of ₹134.50 against the upper price band of ₹126. This 6.75% premium suggests positive market sentiment and potential listing gains for successful allottees.
What GMP Tells Us
The consistent GMP indicates stable market confidence in Amanta Healthcare’s business model and growth trajectory. For investors tracking IPO market trends in 2025, this represents a moderately positive but realistic expectation.
Company Fundamentals That Attracted Investors
Manufacturing Excellence
The company operates four LVP and three SVP manufacturing lines at its WHO-GMP certified, 66,852 sq. meter facility in Hariyala, District Kheda, Gujarat, producing over 45 generic products across six therapeutic segments. This diversified manufacturing capability positions them well in the competitive pharmaceutical landscape.
Financial Performance Highlights
Amanta Healthcare’s net worth increased by more than 45% to ₹96.39 crore in FY2025, compared to ₹66.29 crore in FY2024, showcasing robust financial growth that justified investor enthusiasm.
Operational Efficiency
With an impressive 96% capacity utilization as of March 31, 2025, and a team of 1,718 employees, the company demonstrates operational excellence that appeals to institutional investors seeking sustainable growth stories.
How to Check Allotment Status
Online Methods
Investors can check their allotment status through multiple channels:
- BSE Website: Visit the official BSE portal and search for Amanta Healthcare
- Registrar Website: Check with the official registrar handling the IPO
- ASBA Bank: Log into your ASBA-enabled bank account for status updates
Important Dates to Remember
The basis of allotment was finalized on September 4, 2025, with successful applicants receiving confirmation through email and SMS notifications.
Investment Thesis and Market Position
Sector Advantages
The pharmaceutical sector offers defensive characteristics with steady demand growth, making Amanta Healthcare an attractive proposition for investors seeking healthcare sector exposure.
Competitive Positioning
As a well-established manufacturer with diverse product portfolio and wide domestic and international marketing network, Amanta Healthcare is positioned to benefit from India’s growing pharmaceutical export market.
Risk Factors to Consider
Market Competition
While industry growth is expected to benefit the company, challenges remain in terms of increasing competition, requiring continued innovation and operational efficiency.
Regulatory Environment
The pharmaceutical sector operates under strict regulatory oversight, making compliance costs and regulatory changes potential risk factors for investors to monitor.
Listing Day Expectations
Market Sentiment
With the strong subscription numbers and positive GMP, market participants are cautiously optimistic about the listing performance. However, broader market conditions and sector sentiment on listing day will influence actual performance.
Long-term Outlook
For investors considering long-term positions, Amanta Healthcare’s diversified product portfolio and strong operational metrics provide a solid foundation, though success will depend on execution of growth strategies and market expansion plans.
The overwhelming investor response to Amanta Healthcare’s IPO reflects growing confidence in India’s pharmaceutical sector and the company’s specific growth story. Whether this translates to listing gains remains to be seen, but the strong fundamentals provide a solid base for long-term value creation.
Stay updated with the latest IPO news, market analysis, and investment guides at TechnoSports for comprehensive coverage of India’s financial markets.
FAQs
Q: When is Amanta Healthcare expected to list on stock exchanges and what is the current Grey Market Premium?
A: Amanta Healthcare is scheduled to list on BSE and NSE on September 9, 2025. The current Grey Market Premium (GMP) stands at ₹8.50, suggesting an expected listing price of ₹134.50 against the upper price band of ₹126, indicating a potential 6.75% gain for successful allottees.
Q: How can investors check their Amanta Healthcare IPO allotment status?
A: Investors can check their allotment status through multiple channels: the official BSE website, the registrar’s portal, or their ASBA-enabled bank account. The basis of allotment was finalized on September 4, 2025, and successful applicants receive confirmation via email and SMS notifications.
